Dyne Therapeutics, Inc. (NASDAQ:DYN) Stake Cut by Invesco Ltd.

Invesco Ltd. cut its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 4.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,323 shares of the company’s stock after selling 2,099 shares during the quarter. Invesco Ltd.’s holdings in Dyne Therapeutics were worth $950,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. KBC Group NV lifted its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Dyne Therapeutics during the fourth quarter valued at about $257,000. Magnetar Financial LLC acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at $263,000. E Fund Management Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after acquiring an additional 1,249 shares during the period. Finally, Legato Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $305,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $11.99 on Friday. The stock’s fifty day moving average price is $10.62 and its 200 day moving average price is $19.13. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $47.45. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -3.37 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. Research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 6,237 shares of company stock worth $77,760 over the last three months. Company insiders own 20.77% of the company’s stock.

Analysts Set New Price Targets

DYN has been the subject of several research reports. Scotiabank initiated coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. BMO Capital Markets began coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price objective for the company. Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.